AVITA Medical Sticks to Recovery Narrative Amid Reimbursement Headwinds and Cash Constraints

What happened

AVITA Medical hosted a shareholder call where management reiterated expectations for a revenue recovery in the second half of 2025, driven by reimbursement advocacy and the launch of RECELL GO, but provided no quantitative targets. The prepared remarks acknowledged that reimbursement changes pressured provider economics and contributed to demand softness in early 2025, consistent with the prior 10-Q disclosure. Despite an optimistic tone, the company did not announce new coverage wins or material adoption metrics, leaving the recovery path unconfirmed. Cash and cash equivalents remain thin at approximately $12 million, with ongoing interest payments raising the risk of dilutive financing if the turnaround slips. The call offered no substantive shift in strategy or evidence that the underlying utilization trends have inflected positively.

Implication

If AVITA executes on RECELL GO adoption and secures durable reimbursement coverage, the platform's differentiation could support re-rating, but the slim balance sheet and lack of catalysts keep the risk/reward balanced; patience is warranted.

Thesis delta

The call provided no material new information or catalysts that alter our neutral stance. The bullish case remains contingent on visible procedure growth and funding clarity, neither of which was substantiated. Until evidence emerges, we maintain a HOLD/NEUTRAL posture with a skeptical eye on liquidity.